Khatri P, Abruzzo T, Yeatts S D, Nichols C, Broderick J P, Tomsick T A
Department of Neurology, University of Cincinnati Academic Health Center, Cincinnati, OH 45267-0525, USA.
Neurology. 2009 Sep 29;73(13):1066-72. doi: 10.1212/WNL.0b013e3181b9c847.
Trials of IV recombinant tissue plasminogen activator (rt-PA) have demonstrated that longer times from ischemic stroke symptom onset to initiation of treatment are associated with progressively lower likelihoods of clinical benefit, and likely no benefit beyond 4.5 hours. How the timing of IV rt-PA initiation relates to timing of restoration of blood flow has been unclear. An understanding of the relationship between timing of angiographic reperfusion and clinical outcome is needed to establish time parameters for intraarterial (IA) therapies.
The Interventional Management of Stroke pilot trials tested combined IV/IA therapy for moderate-to-severe ischemic strokes within 3 hours from symptom onset. To isolate the effect of time to angiographic reperfusion on clinical outcome, we analyzed only middle cerebral artery and distal internal carotid artery occlusions with successful reperfusion (Thrombolysis in Cerebral Infarction 2-3) during the interventional procedure (<7 hours). Time to angiographic reperfusion was defined as time from stroke onset to procedure termination. Good clinical outcome was defined as modified Rankin Score 0-2 at 3 months.
Among the 54 cases, only time to angiographic reperfusion and age independently predicted good clinical outcome after angiographic reperfusion. The probability of good clinical outcome decreased as time to angiographic reperfusion increased (unadjusted p = 0.02, adjusted p = 0.01) and approached that of cases without angiographic reperfusion within 7 hours.
We provide evidence that good clinical outcome following angiographically successful reperfusion is significantly time-dependent. At later times, angiographic reperfusion may be associated with a poor risk-benefit ratio in unselected patients.
静脉注射重组组织型纤溶酶原激活剂(rt-PA)的试验表明,从缺血性中风症状发作到开始治疗的时间越长,临床获益的可能性就越低,超过4.5小时可能无获益。静脉注射rt-PA开始的时间与血流恢复的时间之间的关系尚不清楚。需要了解血管造影再灌注时间与临床结局之间的关系,以确定动脉内(IA)治疗的时间参数。
中风介入管理试点试验对症状发作后3小时内的中重度缺血性中风进行静脉/动脉联合治疗。为了分离血管造影再灌注时间对临床结局的影响,我们仅分析了介入过程中(<7小时)成功再灌注(脑梗死溶栓2-3级)的大脑中动脉和颈内动脉远端闭塞情况。血管造影再灌注时间定义为从中风发作到手术结束的时间。良好的临床结局定义为3个月时改良Rankin评分0-2分。
在54例病例中,只有血管造影再灌注时间和年龄独立预测血管造影再灌注后的良好临床结局。随着血管造影再灌注时间的增加,良好临床结局的概率降低(未调整p = 0.02,调整后p = 0.01),并接近7小时内未进行血管造影再灌注的病例。
我们提供的证据表明,血管造影成功再灌注后的良好临床结局显著依赖于时间。在较晚的时间,血管造影再灌注在未选择的患者中可能与不良的风险效益比相关。